Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 826, pseudogene (RNU6-826P) is classified as a non-coding RNA pseudogene derived from the U6 small nuclear RNA family. U6 snRNA genes typically encode the RNA component of spliceosomal U6 snRNP, an essential catalytic participant in pre-mRNA splicing in eukaryotes[1][3]. However, the "pseudogene" designation indicates that RNU6-826P lacks the capacity to produce a functional U6 snRNA molecule, usually due to sequence mutations, insertions, or deletions that disrupt normal transcription or processing[4]. Pseudogenes can sometimes possess regulatory functions—such as acting as decoys for microRNAs, producing regulatory non-coding RNAs, or influencing their parental gene via epigenetic mechanisms—but there is no specific evidence that RNU6-826P has any such role[2]. It is not considered a receptor, enzyme, transporter, transcription factor, or other classical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 826, pseudogene (RNU6-826P).